We compared the two formats of rKE16 antigen-based rapid tests, a flowthrough test (KEFT) and a lateral flow test (KELF), with the rK39 rapid test for the diagnosis of visceral leishmaniasis. Sensitivities with KEFT (99%, 198/200) and rK39 (99.5%, 199/200) were comparable and higher than that with KELF (95.5%, 191/200). In the control groups comprising subjects with diseases from areas of nonendemicity or endemicity and subjects with different diseases, the specificities were comparable for all three rapid tests, except that specificity was higher with KELF in the controls from areas of endemicity.
V
isceral leishmaniasis (VL), or kala-azar, is one of the most neglected diseases, affecting the poorest of the poor in developing countries. Patients with VL present with prolonged fever, splenomegaly, and weight loss, and cases are easily confused with malaria, enteric fever, etc. Antileishmanial drugs are toxic as well as expensive, and therefore, an accurate diagnosis is imperative before starting treatment. Improved serological diagnostic tools are desirable for VL to replace the parasitological diagnosis by invasive splenic aspiration, which carries the risk of severe hemorrhage.
Antileishmanial antibody detection by rapid diagnostic tests (RDTs) is used for the diagnosis of VL. Most RDTs use recombinant K39 antigen, a 39-amino-acid antigen conserved in the kinesin region of Leishmania chagasi syn. infantum (6) (7) (8) . It has shown ϳ100% sensitivity, but in areas with high transmission, the rK39 rapid test is positive in 15 to 32% of healthy individuals (1-3). To make a more specific diagnosis, recombinant antigen rKE16, a 39-amino-acid protein, has been cloned and expressed in Escherichia coli, from the C terminus of the kinesin protein of Leishmania donovani from Indian isolates with high sensitivity and specificity by enzyme-linked immunosorbent assay (ELISA) (4, 5) . This recombinant antigen is immobilized in two different rapid formats, a flowthrough test (KEFT), or Signal KA, and a lateral flow test (KELF), or Crystal KA (Span Diagnostics, Ltd., India).
This study was conducted at the Department of Medicine, Institute of Medical Sciences, Banaras Hindu University (BHU) and at its field site at Kala-azar Medical Research Center (KAMRC), Muzaffarpur, Bihar, India. In this study, 599 subjects were enrolled during January 2010 to March 2012. The study was approved by Ethical Committee of the Institute of Medical Sciences, BHU, and written informed consent was obtained from enrolled subjects.
This study included 200 parasitologically confirmed patients with VL who were between 5 and 65 years of age. Patients with a history of VL, positive HIV serology, or a positive pregnancy test were excluded from study. Controls comprised healthy individuals living in regions of endemicity (n ϭ 134), regions of nonendemicity (n ϭ 132), and patients with other febrile illnesses (n ϭ 133) comprising malaria (n ϭ 25), typhoid (n ϭ 31), dengue (n ϭ 18), amoebic liver abscess (n ϭ 12), renal diseases (n ϭ 32), and tuberculosis (n ϭ 15). Sera were separated from 1 ml blood and stored at Ϫ20°C.
Both the KEFT and KELF formats represent a one-step rapid immunochromatography test (ICTs) for diagnosis of VL and have a shelf life of 1 year. The storage conditions for KEFT and KELF are at 2 to 8°C and 4 to 30°C, respectively. In KEFT, rKE16 is immobilized at the test "T" region of the porous membrane on the test device. As the sample flows through the membrane, antileish- mania antibodies are trapped by immobilized antigens. Nonspecific antibodies are filtered through in washing step. Colloidal gold-protein A reagent, is added in the next step, and it gets bound to the immobilized antigen-antibody complex and gives a pinkish red color dot at the test "T" region for confirmation of VL diagnosis after 2 to 10 min. In KELF, rKE16 is immobilized at the test "T" region of an immunochromatographic strip comprising nitrocellulose membrane. The conjugate-releasing pad of the test device is impregnated with colloidal gold-protein A complex. As the sample passes through the conjugate-releasing pad, antileishmanial antibodies bind colloidal gold with protein A, which moves through the nitrocellulose membrane, binds to the immobilized antigen, and forms a pinkish red test band for confirmation of VL diagnosis after 10 to 15 min. The clinical and laboratory characteristics of patients with VL are given in Table 1 . The sensitivity and specificity of KELF and KEFT compared with the comparator rK39 test (InBios, Seattle, WA) are given in Table 2 .
Accurate and affordable diagnostic tests are essential for the elimination or control of VL. The rK39 strip is widely used for screening of kala-azar patients in India. Despite having 100% sensitivity, it fails to be a "gold standard" diagnostic marker of kalaazar due to its inability to discriminate between clinical and subclinical infections (2) . In a study organized by the World Health Organization examining commercially available RDTs for the diagnosis of VL, both KEFT and KELF have shown similar sensitivities and specificities for VL. Both RDTs were able to detect several species of Leishmania like L. donovani and L. infantum (9) .
In this study, the sensitivities with KEFT (99%) and rK39 (99.5%) were similar, although significantly higher than that with KELF (95.5%) (rK39 versus KELF, P ϭ 0.013; KEFT versus KELF, P ϭ 0.023). In healthy subjects from areas of endemicity, the specificities of both KEFT and KELF were significantly higher than that of the rK39 test (KEFT versus rK39, P ϭ 0.007; KELF versus rK39, P ϭ Ͻ0.001). When we compared the specificities of KELF and KEFT in controls from areas of endemicity, specificity was significantly higher (P ϭ 0.023) with KELF, but this could also be the result of the lower sensitivity of KELF, and thus this makes it a poor candidate for use in the diagnosis of VL. Pairwise comparison of receiver operating characteristic curves revealed no significant difference between KEFT and KELF, although the areas under the curve were significantly higher for KEFT (0.954 Ϯ 0.0124; 95% confidence interval [CI], 0.926 to 0.974; P ϭ 0.0008) and KELF (0.955 Ϯ 0.0116; 95% CI, 0.927 to 0.975; P ϭ 0.0067) compared to that for rK39 (0.912 Ϯ 0.0165; 95% CI, 0.876 to 0.940).
The highly similar sensitivity and better specificity of KEFT give it a slight edge over rK39 RDT in the diagnosis of VL.
We also calculated kappa values to know the agreement between the tests used in this study. The kappa values range from 0 (no agreement) to 1 (perfect agreement). There was excellent agreement between KEFT and KELF in the control groups from areas of nonendemicity and those with different diseases, with kappa values of 0.97 and 0.98 for KEFT and 0.94 and 0.95 for KELF, respectively. Results with rKE16 antigen using the ELISA format (5) were reproducible in the KEFT format. Although KEFT had excellent and comparable sensitivity to rK39, it had a significantly higher specificity in healthy controls from regions of endemicity, and thus it can be considered an excellent alternative test for the serodiagnosis of VL in India. 
